- Home
- AGYS vs DNLI Comparison
AGYS vs DNLI Comparison
Compare AGYS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGYS
- DNLI
- Stock Information
- Founded
- AGYS 1963
- DNLI 2013
- Country
- AGYS United States
- DNLI United States
- Employees
- AGYS N/A
- DNLI N/A
- Industry
- AGYS EDP Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGYS Technology
- DNLI Health Care
- Exchange
- AGYS Nasdaq
- DNLI Nasdaq
- Market Cap
- AGYS 3.0B
- DNLI 2.5B
- IPO Year
- AGYS N/A
- DNLI 2017
- Fundamental
- Price
- AGYS $125.94
- DNLI $19.09
- Analyst Decision
- AGYS Strong Buy
- DNLI Strong Buy
- Analyst Count
- AGYS 5
- DNLI 13
- Target Price
- AGYS $139.20
- DNLI $32.64
- AVG Volume (30 Days)
- AGYS 206.0K
- DNLI 1.4M
- Earning Date
- AGYS 10-27-2025
- DNLI 11-06-2025
- Dividend Yield
- AGYS N/A
- DNLI N/A
- EPS Growth
- AGYS N/A
- DNLI N/A
- EPS
- AGYS 0.86
- DNLI N/A
- Revenue
- AGYS $299,809,000.00
- DNLI N/A
- Revenue This Year
- AGYS $16.52
- DNLI N/A
- Revenue Next Year
- AGYS $17.16
- DNLI $94,232.03
- P/E Ratio
- AGYS $146.66
- DNLI N/A
- Revenue Growth
- AGYS 17.77
- DNLI N/A
- 52 Week Low
- AGYS $63.71
- DNLI $10.57
- 52 Week High
- AGYS $145.25
- DNLI $26.18
- Technical
- Relative Strength Index (RSI)
- AGYS 55.23
- DNLI 69.43
- Support Level
- AGYS $118.00
- DNLI $16.85
- Resistance Level
- AGYS $127.41
- DNLI $18.21
- Average True Range (ATR)
- AGYS 4.65
- DNLI 1.17
- MACD
- AGYS -0.94
- DNLI 0.23
- Stochastic Oscillator
- AGYS 53.20
- DNLI 90.65
About AGYS Agilysys Inc.
Agilysys Inc provides hospitality software delivering cloud-native SaaS and on-premise solutions for hotels, resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It derives maximum revenue from the provision of software subscription and maintenance services, followed by the provision of professional services, and the sale of products (proprietary software licenses, third-party hardware, and operating systems). Agilysys operates across North America, Europe, the Middle East, Asia-Pacific, and India.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.